INVO Bioscience, Inc. - 8-K Filing Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 27, 2023 (filed January 3, 2024), concerns INVO Bioscience, Inc. (Nasdaq: INVO). The filing details material amendments to a pending merger with NAYA Biosciences, Inc., a new securities purchase agreement, and an extension of outstanding convertible notes.
Key Financial Metrics and Agreements
- Merger Extension: The termination date for the merger agreement with NAYA Biosciences, Inc. has been extended to April 30, 2024.
- Interim Financing (PIPE): The closing condition for an interim private offering was modified. NAYA Biosciences agreed to purchase at least $2,000,000 of Series A Preferred Stock at $5.00 per share (400,000 shares) in tranches. The initial $500,000 tranche was due December 29, 2023, but the filing notes this amount had not yet been received as of the report date.
- Convertible Notes: The company issued $410,000 in convertible notes in 2023 (originally maturing December 31, 2023). Holders consented to extend the maturity date to June 30, 2024.
- Debt Terms Adjustment: As an incentive for the note extension, the fixed conversion price for the notes and the exercise price for associated warrants were reduced from $10.00/$12.00 and $20.00, respectively, to $2.25.
- Liquidity: The filing indicates the company has past due accrued payables that the interim financing is intended to address.
Material Changes and Unusual Items
- Executive Compensation: The CEO and CFO voluntarily reduced their annual base salaries from $260,000 and $215,000 to $105,000, effective August 16, 2023. These salaries reverted to original amounts on January 1, 2024.
- Financing Structure: The interim funding requirement shifted from a common stock offering at a market premium to a preferred stock offering at a fixed price of $5.00 per share.
Outlook, Risks, and Contingencies
The merger closing is contingent upon the consummation of the interim private offering. If the company fails to receive the initial gross proceeds per the agreed schedule, it retains the right to secure funding from third parties on reasonable terms. The filing highlights liquidity risks, specifically the need to cover past due accrued payables and support fertility business activities for 12 months post-closing.
Investor Verification Checklist
- Confirm receipt of the initial $500,000 tranche from NAYA Biosciences, which was outstanding as of the filing date.
- Verify the status of the remaining tranches of the $2,000,000 preferred stock offering scheduled through February 2024.
- Assess the impact of the conversion price reduction to $2.25 on existing shareholder dilution.
- Monitor the company's ability to secure alternative third-party funding if the NAYA PIPE schedule is not met.
- Review the updated cash runway given the extension of the merger deadline to April 30, 2024.